Monday August 23, 1999

COMPANY PRESS RELEASE

Kraig McKee Named Vice President of Sales - U.S. for Transgenomic, Inc.

Transgenomic, Inc. announced the appointment of Kraig McKee as Vice President of Sales – U.S. for the Company. McKee will report to Jed Doyle, Executive Vice President of Operations for Transgenomic, and will have the responsibility for driving sales of instrumentation in the States. He will be headquartered in the San Jose, CA office.

"It's so exciting to be joining a Company that has the opportunity to play such a key role in the advancement of genetic research and disease cure discovery," said McKee. "Transgenomic is committed to being the leader in providing enabling technology platforms in the Life Sciences Arena, and I am delighted to join a Company dedicated to fulfilling this vision. These will be exciting, challenging and rewarding times as we move into the next millennium with our technologies," he stated.

Prior to joining Transgenomic, Kraig held the position of Director of Sales for Bayer Diagnostics, responsible for the achievement of a fifty million-dollar budget through the direction a team of 50. Bayer's product portfolio included offerings in Critical Care, Immunoassay, Hematology, General Chemistry and Urine Chemistry.

Additionally, Kraig held positions as Regional Sales Manager, Senior Regional Sales Manager, Area Marketing Manager and National Director in his twelve-year tenure with the organization, and has a B.B.A. in Marketing from Texas Tech University.

Certain statements made by Transgenomic, Inc. in this press release may be forward looking. These may be identified by the use of forward-looking words or phrases such as in the following examples: "anticipate," "believe," "estimated," "think," "planned," "potential," "should," others. Any forward-looking statements are based on the Company's current expectations. The Company undertakes no obligation to publicly release the results of any revisions to any forward looking statement, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Statements in this release should be evaluated in light of these important factors.

For more information contact investorrelations@transgenomic.com.